Galactose
Sponsors
NYU Langone Health, Northwell Health, University of Louisville, University of Aarhus, University of Bath
Conditions
Cardiovascular Risk FactorFocal Segmental GlomerulosclerosisGlucoseHealthyHepatic CancerHepatitis CLipemiaTraumatic Injury
Phase 1
Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability Factor
TerminatedNCT00816478
Start: 2008-12-31End: 2009-12-31Updated: 2015-09-10
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
WithdrawnNCT00816504
Start: 2008-12-31End: 2009-12-31Updated: 2015-09-07
Phase 2
Phase 4
Unknown Phase
Direct Peritoneal Resuscitation Effects in the Damage Control Patient
CompletedNCT01771055
Start: 2012-01-31End: 2016-06-30Updated: 2021-06-16
Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C
CompletedNCT02528461
Start: 2015-01-31End: 2020-01-31Updated: 2020-04-07
sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis
CompletedNCT02702765
Start: 2016-02-29End: 2022-02-28Updated: 2022-11-02
Effect of Galactose Ingestion on Postprandial Lipemia
CompletedNCT03439878
Start: 2018-02-01End: 2018-05-01Updated: 2018-05-24
The GALAXY-1 Project
NCT05986500
Start: 2024-02-12End: 2025-05-31Target: 8Updated: 2024-04-23
Effect of Low Dose Galactose on Glycaemia and Glucose Kinetics
RecruitingNCT07599683
Start: 2026-01-01End: 2029-12-31Target: 25Updated: 2026-07-08
Oral Galactose as a Substrate for Post-Exercise Skeletal Muscle Glycogen Repletion in Individuals With Type 1 Diabetes
Not yet recruitingNCT07774780
Start: 2027-02-01End: 2029-05-31Target: 16Updated: 2026-08-19